NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
Globe Newswire•28/09/2026•08:00 ET
0
ZURICH, Sept. 28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company developing stem-cell-derived therapies for Type 1 Diabetes (T1D), today announced that members of its senior management team will attend the Breakthrough T1D Clinical & Research Congress, taking place October 9–11, 2026, in Philadelphia, Pennsylvania.
During the congress, NewcelX management will be available to meet with researchers, clinicians, investors and potential strategic partners to discuss the Company’s lead program, NCEL-101, and preparations for its planned Phase 1/2a clinical trial in T1D.
Get started
Create a free account to read the full story and Whiz Insights.